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CARDIOTHORACIC TRANSPLANTATIONContinuous flow left ventricular assist device technology has
influenced wait times and affected donor allocation in
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http://dx
1966Objective: Bridge to transplantation patients with continuous flow left ventricular assist devices (cfLVADs)
are assigned United Network for Organ Sharing status 1A or 1B priority while awaiting orthotopic heart
transplantation. We investigated the influence of cfLVAD on the waitlist times and organ allocation.
Methods: The United Network for Organ Sharing database was examined from 2005 to 2012 for patients with
cfLVAD and pulsatile flow LVAD (pLVAD). These 2 cohorts were compared with patients who did not receive
LVAD.
Results: Of 16,476 total orthotopic heart transplantations, 3270 (19.8%) were performed on patients with an
LVAD as a bridge to transplantation. The cfLVAD group had the longest total waitlist time (259.6 days)
compared with the pLVAD (134.6 days) and non-LVAD (121.7 days) groups (P<.001). The cfLVAD group
spent more time in status 1A (44.7 days) than did the pLVAD (32.1 days) and non-LVAD (16.4 days) cohorts
(P<.001). The median waitlist survival was better for the cfLVAD group (1234.0 days) than in the pLVAD
(441.0 days) and non-LVAD (471.0 days) groups (P<.001). The cfLVAD recipients were older, had a greater
body mass index, and more often had diabetes than did pLVAD and non-LVAD patients. The cfLVAD cohort
received hearts from older, more often male donors, with a greater body mass index. Post-transplant survival
was not significantly different among the 3 groups on Kaplan-Meier analysis (P ¼ .12).
Conclusions: Despite being older, less favorable recipients, the cfLVAD patients spent more time in status 1A
and had greater waitlist survival. This might allow cfLVAD patients to receive preferred donor hearts, which
might allow for better post-transplant survival. (J Thorac Cardiovasc Surg 2014;147:1966-71)Supplemental material is available online.
Left ventricular assist devices (LVADs) have increasingly
been used to bridge patients to orthotopic heart transplanta-
tion (OHT).1-3 Currently, patients implanted with an LVAD
await OHT as United Network Organ Sharing (UNOS)
status 1B with a 30-day upgrade to status 1A at the discre-
tion of the transplant center. In addition, patients with anhe Department of Surgery,a Temple University School of Medicine,
elphia, Pa; Department of Public Health,b Temple University, Philadelphia,
nd Division of Cardiac Surgery,c Yale University School of Medicine,
Haven, Conn.
res: Abeel A. Mangi received speaking and consulting fees from Thoratec
ration. All other authors have nothing to disclose with regard to commercial
rt.
d as an oral presentation at the Annual American Heart Association Scientific
ns on November 19, 2013.
d for publication Dec 9, 2013; revisions received Jan 21, 2014; accepted for
ation Feb 4, 2014; available ahead of print March 7, 2014.
for reprints: Abeel A. Mangi, MD, Division of Cardiac Surgery, Yale
rsity School of Medicine, Boardman 204, 330 Cedar St, New Haven,
510 (E-mail: abeel.mangi@yale.edu).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2014.02.001
The Journal of Thoracic and Cardiovascular SurLVAD can be upgraded to status 1A in the event of a device
complication or malfunction.4-7 This organ allocation
protocol was designed in the era in which pulsatile flow
devices (pLVADs) predominated. Since 2007, continuous
flow devices (cfLVADs) have been approved by the Food
and Drug Administration for bridge to transplantation
(BTT), primarily by documentation of improved survival
and decreased complications.1,3,8,9 The goal of the present
study was to determine the effect of cfLVAD use on the
waitlist times and organ allocation.
METHODS
Data Source
After approval from the local institutional review board, the public-use
Standard Transplant Analysis and Research data files were obtained from
the UNOS registry. Because information onmechanical circulatory support
was poorly documented before 2005, we analyzed the data from January
2005 to December 2012. Patients requiring temporary right ventricular
assist devices, biventricular assist devices, or a total artificial heart were
excluded from the present analysis.
The type of LVAD used was not available for patients placed on the
waitlist after LVAD implantation but who did not undergo transplantation.
Thus, to analyze waitlist survival, we designated implantations with LVAD
from 2005 to 2008 as the pLVAD era and implantations from 2009 to 2012
as the cfLVAD era. Previous studies have corroborated that most
LVADs implanted before 2009 were pLVAD, and the vast majority of those
implanted in 2009 and beyond were cfLVAD.10gery c June 2014
Abbreviations and Acronyms
BMI ¼ body mass index
BTT ¼ bridge to transplantation
cfLVAD ¼ continuous flow left ventricular assist
device
LVAD ¼ left ventricular assist device
OHT ¼ orthotopic heart transplantation
pLVAD ¼ pulsatile left ventricular assist device
UNOS ¼ United Network Organ Sharing
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available. Patients receiving the following long-term, continuous flow
devices were placed in the cfLVAD cohort: HeartMate-II, Jarvik 2000,
Micromed DeBakey VAD, Heartware HVAD, Terumo DuraHeart LVAD,
Ventracor VentrAssist LVAD, and Worldheart Levacor LVAD. Patients
whowere bridged to OHTwith a pulsatile devicewere placed in the pLVAD
cohort. The cfLVAD and pLVAD cohorts were compared with the
recipients who had not received any type of mechanical circulatory support
before OHT.
Statistical Analysis
Analysis of variance and the chi-square test were used to examine the
continuous and categorical variables. Continuous variables are presented
as the mean  standard deviation and categorical variables as the
percentage of the total number of data points available for that field.
Survival curves were generated using the Kaplan-Meier method and
compared using the log-rank test. Cox proportional regression analysis
for waitlist mortality was developed in 2 steps. First, the covariates were
run in a univariate analysis as predictors of mortality. Next, the covariates
with P< .20 were entered simultaneously as a multivariate Cox model.
Covariates missing >15% of data in the registry were excluded. All
covariates evaluated in the study are listed in Tables 1 through 3.
Survival was determined using all-cause mortality. Data were analyzed
using Statistical Analysis Systems statistical software, version 9.2 (SAS
Institute, Cary, NC).
RESULTS
Use of LVAD by Era
Of 16,476 total OHTs, 3270 (19.8%) were performed on
patients with an implanted LVAD as BTT. From 2005 to
2008, 1389 (16.3%) of OHTs were performed on patients
with an implanted LVAD as BTT. This number increased
from 2009 to 2012, with 1881 OHTs (23.7%) performed
on patients with an implanted LVAD as BTT (P<.001).
Comparison of Regional Time Spent Waiting to
Transplantation
The total waitlist time by region is shown in Figure 1, A.
The cfLVAD cohort had the longest total waitlist time in
every 1 of all 11 UNOS regions (P< .001). The average
time spent in status 1A by UNOS region is shown in
Figure E1. The cfLVAD group spent the greatest amount
of time in status 1A in 10 of 11 UNOS regions (P<.001).
In UNOS region 8, the pLVAD group spent the longest
time in status 1A (P< .001). In region 8, cfLVAD spent
more time in status 1A than did the non-LVAD group.The Journal of Thoracic and CarComparison of National Time Spent Waiting for
Transplantation
A comparison of the total waitlist time is shown in
Figure 1, B. Patients in the cfLVAD group had the longest
total waitlist time (259.6 days) compared with the pLVAD
(134.6 days) and non-LVAD (121.7 days) groups
(P< .001). The cfLVAD group spent more time in status
1A (44.7 days) than did the pLVAD (32.1 days) and
non-LVAD (16.4 days) cohorts (P<.001; Figure E2). The
cfLVAD cohort also spent the greatest amount of time in sta-
tus 1B compared with the pLVAD and non-LVAD cohorts.Waitlist Survival
Kaplan-Meier survival curves for patients on the waitlist
awaiting OHT are shown in Figure 2, A. Median survival
was significantly better in the cfLVAD group (1234.0
days) than in the pLVAD (441.0 days) and non-LVAD
(471.0 days) groups (P<.001).
The results of the Cox proportional regression analysis for
waitlist mortality are listed in Table 1. Patients undergoing
OHT were considered survivors for this analysis. Compared
with the non-LVADpatients, the pLVADgroupwas associated
with waitlist mortality (hazard ratio [HR], 2.96; 95% confi-
dence interval [CI], 1.14-7.73; P ¼ .03). The cfLVAD group
was not associated with mortality (HR, 1.88; 95% CI, 0.69-
5.16; P ¼ .22). The other factors associated with mortality
included a primary diagnosis of congenital heart disease
(HR, 8.24; 95% CI, 2.47-27.49; P<.001) and repeat trans-
plant orgraft failure (HR,9.30; 95%CI, 3.15-27.41;P<.001).UNOS Status at Transplantation
Of the 2132 cfLVAD patients who underwent OHT, 1728
(81.1%) were status 1A at OHT. In contrast, in the pLVAD
cohort, 656 (84.8%) were status 1A at OHT. The cfLVAD
cohort (n ¼ 999, 46.9%) was less likely to receive OHT
during the 30-day grace period compared with the pLVAD
cohort (n ¼ 461, 59.6%; P< .001). The cfLVAD group
was more likely to undergo OHT in status 1A because of
device complications (n ¼ 729, 34.2%) compared with
the pLVAD group (n ¼ 195, 25.2%; P< .001). Of the
patients in status 1A because of device complications, the
cfLVAD group was more likely to have had device infection
(59.3% vs 48.7%), less likely to have had device
malfunction (8.5% vs 22.1%), less likely to have had
thromboembolism (9.7% vs 16.4%), more likely to have
had life-threatening ventricular arrhythmia (3.7% vs
0.5%), and more likely to have had another or unknown
reason (15.1% vs 8.7; P<.001).Primary Diagnoses in BTT-LVAD Patients
Undergoing OHT
The results of a comparison of the primary diagnoses in
the BTT-LVAD patients who underwent OHT are listed indiovascular Surgery c Volume 147, Number 6 1967
TABLE 1. Multiple variable model for waitlist mortality
Variable HR 95% CI P value
pLVAD era 2.96 1.14-7.73 .03
cfLVAD era 1.88 0.69-5.16 .22
Age (y)
19-39 Reference Reference Reference
18 0.52 0.15-2.48 .49
40-49 0.60 0.15-2.48 .49
50-59 1.38 0.45-3.91 .61
60 1.33 0.43-4.09 .62
Female gender 0.79 0.36-1.73 .56
Congenital heart disease 8.24 2.47-27.49 <.001
Coronary artery disease 1.51 0.62-3.69 .36
Hypertrophic cardiomyopathy <0.001 <0.001->99.99 .99
Restrictive cardiomyopathy <0.001 <0.001->99.99 .99
Valvular heart disease <0.001 <0.001->99.99 .99
Retransplantation or graft failure 9.30 3.15-27.41 <.001
Race
White Reference Reference Reference
Asian 2.20 0.52-9.40 .29
Black 1.46 0.48-4.13 .53
Hispanic 1.41 0.48-4.13 .53
Mechanical ventilation before
transplantation
0.80 0.23-2.78 .72
ECMO before transplantation 0.25 0.06-1.02 .06
HR, Hazard ratio; CI, confidence interval; pLVAD, pulsatile flow left ventricular
assist device; cfLVAD, continuous flow LVAD; ECMO, extracorporeal membrane
oxygenation.
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most likely to have a primary diagnosis of dilated cardiomy-
opathy (54.4%) compared with the pLVAD cohort (50.1%)
and those not requiring LVAD (44.6%; P<.001). Patients
bridged with pLVAD were more likely to have ischemic
cardiomyopathy (45.3%) than were the cfLVAD
(42.3%) and non-LVAD (31.7%) cohorts (P<.001). The
non-LVAD cohort were most likely to have a primary
diagnosis of congenital disease, restrictive cardiomyopathy,TABLE 2. Baseline recipient characteristics
Recipient characteristic pLVAD (n ¼ 774) cfLVA
Age (y) 50.1  12.2 (n ¼ 774) 52.6 
Male gender 662 (85.5) (n ¼ 774) 1786 (8
BMI (kg/m2) 27.5  4.9 (n ¼ 774) 28.2 
Race
White 514 (66.4) (n ¼ 774) 1491 (6
Black 171 (22.1) (n ¼ 774) 480 (2
Hispanic 59 (7.6) (n ¼ 774) 138 (6
Asian 21 (2.7) (n ¼ 774) 61 (2
PVR 2.14  1.48 (n ¼ 540) 2.31 
Diabetes 208 (27.7) (n ¼ 751) 632 (2
Creatinine (mg/dL) 1.29  0.87 (n ¼ 769) 1.28 
Class I PRA panel 10.0  22.0 (n ¼ 719) 8.6 
Class II PRA panel 5.3  18.5 (n ¼ 624) 5.0 
Data presented as mean  standard deviation or n (%), followed by number of patients. p
BMI, body mass index; PVR, pulmonary vascular resistance; PRA, plasma reactive antige
1968 The Journal of Thoracic and Cardiovascular Surhypertrophic cardiomyopathy, valvular heart disease, repeat
transplant and/or graft failure, or some other diagnosis
(Table 2).Baseline Characteristics of BTT-LVAD Patients
Undergoing OHT
The results of a comparison of baseline recipient
characteristics for the BTT-LVAD patients who underwent
OHT are listed in Table 2. The cfLVAD cohort was older
(52.6 years) than the pLVAD (50.1 years) and non-LVAD
(43.1 years) cohorts (P< .001). The cfLVAD cohort had
the greatest body mass index (BMI) (28.2 kg/m2) compared
with the pLVAD (BMI, 27.5 kg/m2) and non-LVAD (BMI,
24.9 kg/m2) cohorts (P< .001). The recipient creatinine
level was greater in the pLVAD (1.29 mg/dL) and cfLVAD
(1.28 mg/dL) groups than in the non-LVAD (1.23 mg/dL)
group (P< .001). The cfLVAD group (29.6%) was also
more likely to have diabetes than the pLVAD (27.7%)
and non-LVAD (19.9%) groups (P<.001).
The class I plasma reactive antigen panel results were
greater in the pLVAD (10.0%) and cfLVAD (8.6%) cohorts
than in the non-LVAD (6.2%) cohort (P<.001). The class II
plasma reactive antigen panel results and the requirement
for inhaled nitric oxide at OHT were not significantly
different among the 3 groups.Donor Characteristics for All BTT-LVAD Patients
Undergoing OHT
The cardiac donor hearts used in the BTT-LVAD patients
who underwent OHT were compared (Table 3). The donor
hearts used for the cfLVAD cohort were slightly older
(31.2 years) than those for the pLVAD (30.6 years) and
non-LVAD (27.0 years) cohort (P<.001). The donor hearts
used for the pLVAD cohort (78.8%) and cfLVAD cohort
(78.2%) were more likely to be from males than were those
for the non-LVAD cohort (67.3%; P<.001). Donor BMID (n ¼ 2188) Non-LVAD (n ¼ 13,206) P value
12.4 (n ¼ 2188) 43.1  21.9 (n ¼ 13,206) <.001
1.6) (n ¼ 2188) 9085 (68.8) (n ¼ 13,206) <.001
5.1 (n ¼ 2188) 24.9  6.1 (n ¼ 13,135) <.001
8.1) (n ¼ 2188) 8777 (66.5) (n ¼ 13,206) <.001
1.9) (n ¼ 2188) 2541 (19.2) (n ¼ 13,206) <.001
.3) (n ¼ 2188) 1275 (9.7) (n ¼ 13,206) <.001
.8) (n ¼ 2188) 430 (3.3) (n ¼ 13,206) <.001
1.97 (n ¼ 1809) 2.63  2.83 (n ¼ 9411) <.001
9.6) (n ¼ 2137) 2587 (19.9) (n ¼ 12,997) <.001
0.72 (n ¼ 2183) 1.23  1.05 (n ¼ 13,090) .03
20.2 (n ¼ 2052) 6.2  17.5 (n ¼ 12,158) <.001
15.5 (n ¼ 1946) 5.6  17.5 (n ¼ 11,343) .41
LVAD, Pulsatile flow left ventricular assist device; cfLVAD, continuous flow LVAD;
n.
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TABLE 3. Baseline donor characteristics
Donor characteristic pLVAD (n ¼ 774) cfLVAD (n ¼ 2188) Non-LVAD (n ¼ 13,206) P value
Age (y) 30.6  11.3 (n ¼ 774) 31.2  10.9 (n ¼ 2188) 27.0  14.8 (n ¼ 13,206) <.001
Male gender 610 (78.8) (n ¼ 774) 1710 (78.2) (n ¼ 2188) 8883 (67.3) (n ¼ 13,206) <.001
BMI (kg/m2) 27.5  5.4 (n ¼ 774) 27.5  5.5 (n ¼ 2188) 25.2  6.2 (n ¼ 13,205) <.001
Diabetes 16 (2.1) (n ¼ 770) 62 (3.7) (n ¼ 2181) 355 (2.7) (n ¼ 13,167) .52
Ischemic time (h) 3.44  1.13 (n ¼ 753) 3.32  1.06 (n ¼ 2152) 3.29  1.09 (n ¼ 12,848) .001
Total HLA mismatches 4.68  1.06 (n ¼ 649) 4.63  1.11 (n ¼ 1905) 4.64  1.08 (n ¼ 11,547) .54
ABO-compatible donor 122 (15.8) (n ¼ 774) 275 (12.6) (n ¼ 2188) 2253 (17.1) (n ¼ 13,205) <.001
Race mismatch 377 (48.7) (n ¼ 774) 1168 (53.4) (n ¼ 2188) 6719 (50.9) (n ¼ 13,206) .04
Clinical signs of infection 318 (42.2) (n ¼ 753) 1236 (57.7) (n ¼ 2143) 6721 (52.1) (n ¼ 12,897) <.001
History of cocaine use 105 (13.9) (n ¼ 756) 338 (15.8) (n ¼ 2137) 1519 (11.7) (n ¼ 12,991) <.001
History of cancer 12 (0.02) (n ¼ 770) 35 (1.6) (n ¼ 2183) 188 (1.4) (n ¼ 13,163) .79
Data presented as mean  standard deviation or n (%), followed by number of patients. pLVAD, Pulsatile flow left ventricular assist device; cfLVAD, continuous flow LVAD;
BMI, body mass index; HLA, human leukocyte antigen.
Taghavi et al Cardiothoracic Transplantationwas greatest in the cfLVAD (27.5 kg/m2) and pLVAD (27.5
kg/m2) cohorts as compared with the non-LVAD cohort
(25.2 kg/m2; P< .001). The ischemic time was lowest in
the non-LVAD group (3.29 hours) compared with the
cfLVAD (3.32 hours) and pLVAD (3.44 hours) groups. A
history of diabetes and total human leukocyte antigen mis-
matches was not significantly different among the 3 groups.
The number of ABO compatible donors was lowest in the
cfLVAD group (12.6%) compared with the pLVAD
(15.8%) and non-LVAD (17.1%) groups (P<.001).Morbidity and Mortality for BTT-LVAD Patients
After OHT
The length of stay was shorter for the cfLVAD group
(20.0 days) than for the non-LVAD group (20.8 days;
P ¼ .01). The length of stay was longest in the pLVAD
cohort (23.0 days; P ¼ .01). The number of acute rejection
episodes at the index hospitalization was greatest in the
cfLVAD group (19.3%), followed by the pLVAD (16.2%)
and non-LVAD (14.9%) cohorts (P<.001).
The Kaplan-Meier survival curves for the patients who
underwent OHT are shown in Figure 2, B. Survival was
not significantly different among the 3 groups (P ¼ .12).
The median follow-up time was 1448.0 days for the pLVADFIGURE 1. Total waitlist time stratified by (A) all 11 United Network Organ
device; pLVAD, pulsatile flow left ventricular assist device; cfLVAD, continuou
The Journal of Thoracic and Carcohort, 422.0 days for the cfLVAD cohort, and 954.0 days
for the non-LVAD cohort.
The Kaplan-Meier survival curves for the cfLVAD-BTT
patients who underwent OHT as status 1A during their
30-day grace period, status 1A by exception, or status 1B
are shown in Figure 2, C. Survival was not significantly
different among these 3 groups (P ¼ .14).
A comparison of survival by era in the non-LVAD cohort
is shown in Figure E3. Survival by Kaplan-Meier analysis
was significantly better in the non-LVAD recipients in the
more recent cfLVAD era (P ¼ .01).DISCUSSION
The current UNOS allocation protocol was designed
during the era of older generation pLVADs.7 The newer
generation of cfLVADs has proved to be durable, with
significantly fewer reported device malfunctions, and
have simultaneously produced significant improvements
in morbidity and mortality as BTT patients await transplan-
tation.1,3,7,8 These 2 metrics have reshaped how donor
hearts are allocated. The goal of the present study was to
determine how the advent of the cfLVAD has influenced
the waiting times and organ allocation using a national
database.Sharing (UNOS) regions and (B) nationally. LVAD, Left ventricular assist
s flow left ventricular assist device.
diovascular Surgery c Volume 147, Number 6 1969
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FIGURE 2. Survival for patients (A) on the waitlist, (B) after orthotopic heart transplantation, and (C) continuous flow left ventricular assist device
(cfLVAD) patients after orthotopic heart transplantation. LVAD, Left ventricular assist device; pLVAD, pulsatile flow LVAD.
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survived to OHT had less favorable profiles compared
with the pLVAD and non-LVAD cohorts. They were older,
had a greater BMI, were more likely have diabetes, and
had worse renal function. Despite these findings, these
patients were able to compete for high-quality donors.
The donors to the cfLVAD recipients were more likely to
be men, have a greater BMI, and to be ABO identical.
The ability to compete for high-quality donors in the
cfLVAD cohort was likely multifactorial. Our analysis has
suggested that the cfLVAD cohort experienced enhanced
waitlist survival compared with the pLVAD and non-
LVAD cohorts. cfLVAD was not associated with waitlist
mortality. The excellent outcomes with cfLVAD in patients
with end-stage heart failure and decreased device failure
compared with pLVAD have also been well documented
in previous studies.1,8-10 The improved survival seen for
BTT patients with cfLVAD was observed across all 11
UNOS regions, and when the US waitlist activity was
viewed as a composite, and appeared to translate into
longer time spent alive on the waitlist. This, in turn, might
allow transplant centers to wait for a preferable donor. In
addition, sophisticated transplant centers with knowledge
of the local and regional waitlist population could
legitimately choose to use the 30-day status 1A grace period
at any point during a patient’s post-LVAD life, thus
optimizing chances of a transplant with a high-quality
donor. Thus, 999 (45.7%) of the 2188 cfLVAD patients
underwent OHT during the 30-day status 1A grace period.
This trend has been observed nationwide, because the
cfLVAD patients in 10 of the 11 UNOS regions spent the
longest time in status 1A. Dardas and colleagues11 also
observed that cfLVAD patients were far more likely to be
status 1A, despite their more favorable adverse event
profile, compared with the patients awaiting OHT without
an LVAD. Even among the cfLVAD patients who were
listed for, and underwent, OHT as status 1A because of a
device complication (n ¼ 729, 34.2% of all cfLVAD
patients)—because the complication types were more likely
to be infectious or arrhythmogenic, in contrast to those in1970 The Journal of Thoracic and Cardiovascular Surthe pLVAD era—the patients were more likely to survive
to transplantation and to have post-transplant survival
similar to that of their peers undergoing OHT as status 1A
by the 30-day grace period and those in status 1B. All these
factors undoubtedly affect the ability to obtain preferred
donor hearts for cfLVAD patients.
The selection of more favorable donors for cfLVAD
patients might allow better outcomes after OHT. In the
present study, the BTT patients with cfLVAD had a shorter
length of stay than did the non-LVAD group, despite having
a greater incidence of acute rejection episodes at the index
hospitalization. BTT patients are known to have a greater
rejection risk owing to sensitization12; however, this does
not necessarily result in worse outcomes owing to
effective immunosuppressive regiments.13 We observed
no difference in survival between the cfLVAD and
non-LVAD cohorts. However, the follow-up time was
relatively short, because information on LVADs was only
reliably available in UNOS starting in 2005. Previous
studies have shown that BTT patients with a cfLVAD had
survival at least equivalent to that of non-LVAD
patients.14-16 However, these studies were again limited
by the short-term follow-up period because the cfLVAD
technology is relatively new. Additional studies are needed
to determine whether patients bridged to OHTwith cfLVAD
will experience better long-term post-OHT outcomes.
To determine whether the survival of OHT recipients in
the non-LVAD cohort was a result of receiving less
favorable donor hearts, we compared the non-LVAD
recipients from 2005 to 2008 with those in the non-LVAD
cohort from 2009 to 2012. We found that non-LVAD
patients in the more recent era actually had slightly better
survival (Figure E3). However, this improved survival in
the more recent era could have resulted from a number of
factors that could not be accounted for in the present study,
such as improved medical therapy and immunosuppressive
regimens. The International Society for Heart and Lung
Transplantation annual report verified that survival after
OHT has continued to improve in more recent years.3
Additional studies are warranted to determine whethergery c June 2014
Taghavi et al Cardiothoracic Transplantationoutcomes in non-LVAD patients have worsened in the era of
the cfLVAD.
As the outcomes with cfLVAD-BTT patients have
continued to improve, many investigators have called for
a re-evaluation of the current UNOS organ allocation
protocol.7,11,17 The current protocol was designed for the
pLVAD era,7 in which device complications were more
numerous and survival was not as good. The goal of the
present protocol was to maximize the allocation of donor
hearts to patients with the greatest likelihood of dying while
waiting for a donor organ. However, because cfLVAD
patients have continued to have unprecedented outcomes,
patients receiving donor hearts are no longer the ones at
greatest risk of mortality. Our study has indicated that
more and more patients have been bridged to OHT with
LVAD. In the pLVAD era, 17% of patients were BTT, and
this increased to 23% in the cfLVAD era. Some institutions
have reported an even greater acceptance of device
technology, with up to 64% of OHT patients being BTT
with a cfLVAD.7 With more and more cfLVAD patients
added to the waitlist, it might not be unreasonable to
re-assess the current donor heart allocation policy to
facilitate an equitable distribution of donor hearts.
The present study was not without limitations, including
those inherent to retrospective registry analysis. The
database did not include all relevant confounders, such as
the immunosuppressive regimen type or socioeconomic
factors. In addition, the study was limited by the relatively
short follow-up time, because information on LVADs did
not become available in the UNOS database until 2005.
Finally, the type of device implanted was not available for
patients who were on the waitlist but had not undergone
transplantation. Thus, when analyzing waitlist mortality,
we considered all patients implanted with an LVAD from
2005-2008 as pLVAD and those implanted from 2009 to
2012 as cfLVAD.
In conclusion, despite being older and less favorable
recipients, the patients bridged to OHTwith cfLVAD spent
more time as status 1A and had greater waitlist survival.
This might allow cfLVAD patients to receive preferred
donor hearts, which might allow them to have greater
post-OHT survival. Because of these findings, it might be
time to revisit the current UNOS donor allocation system.The Journal of Thoracic and CarReferences
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FIGURE E1. Average time as status 1A stratified by all 11 United
Network Organ Sharing (UNOS) regions. LVAD, Left ventricular assist
device; pLVAD, pulsatile flow left ventricular assist device; cfLVAD,
continuous flow left ventricular assist device.
FIGURE E2. Time patients spent as status 1A, status 1B, and status 2 na-
tionally. LVAD, Left ventricular assist device; pLVAD, pulsatile flow left
ventricular assist device; cfLVAD, continuous flow left ventricular assist
device.
FIGUREE3. Comparison of survival for non-left ventricular assist device
(LVAD) transplant recipients in the pulsatile flow (2005-2008) and contin-
uous flow (2009-2012) eras.
TABLE E1. Primary diagnoses of transplant recipients
Diagnosis pLVAD (n ¼ 749) cfLVAD (n ¼ 2132) Non-LVAD (n ¼ 12,747) P value
Dilated cardiomyopathy 375 (50.1) 1159 (54.4) 5682 (44.6) <.001
Coronary artery disease 339 (45.3) 902 (42.3) 4036 (31.7) <.001
Congenital disease 7 (0.9) 11 (0.5) 1382 (10.8) <.001
Restrictive cardiomyopathy 8 (1.1) 13 (0.6) 479 (3.8) <.001
Hypertrophic cardiomyopathy 5 (0.7) 23 (1.1) 323 (2.5) <.001
Valvular heart disease 10 (1.3) 18 (0.8) 222 (1.7) <.001
Retransplantation/graft failure 5 (0.7) 6 (0.3) 618 (4.9) <.001
Other 0 (0.0) 0 (0.0) 5 (0.04) <.001
Data presented as n (%). pLVAD, Pulsatile flow left ventricular assist device; cfLVAD, continuous flow LVAD.
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